Serotonin 1A Agonists and Cognition in Schizophrenia
SchizophreniaSchizoaffective DisorderExamines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder,...
SchizophreniaSchizoaffective Disorder3 moreThis twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective disorder, major depression or bipolar disorder with psychotic features. This study evaluates symptom response as well as general health indicators such as body mass index, glucose, prolactin, and cholesterol levels at baseline, month (M)1, M3, M6 and M12.
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
SchizophreniaAssess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.
Cognitive Enhancement Therapy for Early-Stage Schizophrenia
SchizophreniaThis study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated...
SchizophreniaPsychotic DisordersTo assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode schizophrenia/schizophreniform disorder.
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine...
SchizophreniaThe primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
Clinical Study Of Schizophrenia in Both Men and Women
SchizophreniaThe objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.
Is Cognitive Training an Option?
SchizophreniaSchizoaffective1 moreThe purpose of the study is to evaluate the feasibility of implementing cognitive training with 40 patients living with schizophrenia and schizoaffective disorder. The study aims to explore if cognitive training as an intervention can improve cognition, symptomology, social cognition, and psychosocial function which has been determined through literature to be impacted within this population. The results of this study will help shed light on utilizing additional resources to aid in decreasing relapse and continued hospitalizations.
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Schizoaffective DisorderSchizophrenia2 moreTesting an mHealth mobile interventionist texting program on illness management.
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis...
SchizophreniaSchizophrenia Relapse1 moreThis open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the three years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with schizophrenia spectrum disorder.